Date: 2017-09-21
Type of
information: Initiation of development program
phase:
Announcement:
Company: Transgene (France)
Product: Invir.IO™
Action
mechanism:
- oncolytic virus/immunotherapy product. Invir.IO™ is a new technology platform dedicated to the design of the next generation of oncolytic viruses. The platform is based on a proprietary technology.
- The uncontrolled proliferation of cancer cells is made possible via a number of immunosuppressive mechanisms, which allow the tumor to escape the immune system. These complex cellular and metabolic mechanisms occur in the tumor microenvironment. Transgene’s oncolytic viruses are designed to directly and selectively destroy cancer cells by the intracellular replication of the virus in the cancer cell (oncolysis). Oncolysis induces an immune response against tumors (immunogenic lysis) that it is targeting. In addition, the replication of the virus allows the expression of the genes carried by the oncolytic viral genome including therapeutic “weapons” that have been specifically designed to attack the tumor. Optimized oncolytic viruses to attack the tumor on several fronts and improve cancer treatments
Most immune effector molecules are very effective locally, but can be toxic when administered systemically. The local expression of such therapeutic payloads can significantly augment the anti-cancer effects of viral oncolysis.
Disease:
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news: • On September 21, 2017, Transgene announced the launch of Invir.IO™, its new technology platform dedicated to the design of the next generation of oncolytic viruses. Invir.IO™ will allow Transgene to generate a variety of multifunctional immunotherapies aimed at modulating the tumor micro-environment.Transgene has already demonstrated that its oncolytic viruses derived from its new proprietary Invir.IO™ platform attack tumors on several fronts and can:
• induce an immunogenic cancer cell death
• and express several “anti-cancer weapons” in the tumor, such as cytokines, chemokines, enzymes and/or monoclonal antibodies2 or minibodies.
Transgene’s unique know-how will enable the Invir.IO™ platform to design, produce and develop, in a very efficient way, multiple product candidates either alone or through partnerships.
Is
general: Yes
